Delivery of Mitogen-Activated Protein Kinase Inhibitor for Hepatocellular Carcinoma Stem Cell Therapy
Source abstract
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant human tumors worldwide, but no effective therapeutic options are currently available. The cancer stem cell (CSC) has proven to play a central role in the development, metastasis, and recurrence of HCC. In this study, we report a dual functional mitogen-activated protein kinase inhibitor (U0126)-based therapy for treating both bulk HCC and HCC CSCs, using poly(ethylene glycol)-b-poly(d,l-lactide) (PEG-PLA) nanoparticles as the drug carrier. It is demonstrated that nanoparticle encapsulation enhanced the cell uptake of U0126 in HCC CSCs and that enhanced endocytosis lead to augmented cytotoxicity of U0126 in HCC CSCs. Moreover, the nanoparticle encapsulation increased the inhibition of self-renewal capability, prolonged the circulation time, and increased the tumor accumulation of U0126 when compared with the use of the free inhibitor. The systemic delivery of U0126 remarkably enhanced the suppression of tumor development with decreased CSCs in the HepG2 xenograft simultaneously with reduced systemic toxicity.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Angiogenesis and VEGF in Cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science & Technology of China, Hefei, Anhui 230027, China
Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China
High Magnetic Field Laboratory of CAS, University of Science and Technology of China, Hefei, Anhui 230026, China
Funding
Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China
References (56)
Show source-provided references
1. Avila M. A. · Oncogene · 2006 · 25 · 386610.1038/sj.onc.1209550 ↗
2. Llovet J. M. · J. Hepatol. · 2008 · 48 · S2010.1016/j.jhep.2008.01.022 ↗
3. Aravalli R. N. · Hepatology · 2008 · 48 · 204710.1002/hep.22580 ↗
4. Haraguchi N. · J. Clin. Invest. · 2010 · 120 · 332610.1172/JCI42550 ↗
5. Chen X. · J. Hepatol. · 2011 · 55 · 83810.1016/j.jhep.2010.12.043 ↗
6. Bodzin A. S. · J. Cell. Physiol. · 2012 · 227 · 294710.1002/jcp.23041 ↗
7. Piao L. S. · Cancer Lett. · 2012 · 315 · 12910.1016/j.canlet.2011.10.012 ↗
8. Suetsugi A. · Biochem. Biophys. Res. Commun. · 2006 · 351 · 82010.1016/j.bbrc.2006.10.128 ↗
9. Yin S. · Int. J. Cancer · 2007 · 120 · 144410.1002/ijc.22476 ↗
10. Ma S. · Cell Stem Cell · 2010 · 7 · 69410.1016/j.stem.2010.11.010 ↗
11. Kim H. · Hepatology · 2011 · 54 · 170710.1002/hep.24559 ↗
12. Sun Y. F. · Hepatology · 2013 · 57 · 145810.1002/hep.26151 ↗
13. Sun T. M. · Biomaterials · 2014 · 35 · 83610.1016/j.biomaterials.2013.10.011 ↗
14. Ke X. Y. · Biomaterials · 2014 · 35 · 109610.1016/j.biomaterials.2013.10.049 ↗
15. Li R. J. · J. Controlled Release · 2011 · 49 · 281
16. Zhou Y. · J. Controlled Release · 2013 · 172 · 94610.1016/j.jconrel.2013.09.005 ↗
17. Zhao W. · Cancer Cell · 2013 · 23 · 54110.1016/j.ccr.2013.02.025 ↗
18. Lewis T. S. · Adv. Cancer Res. · 1998 · 74 · 4910.1016/S0065-230X(08)60765-4 ↗
19. Ballif B. A. · Cell Growth Differ. · 2001 · 12 · 397
20. Krueger J. S. · Oncogene · 2001 · 20 · 420910.1038/sj.onc.1204541 ↗
21. Cowley S. · Cell · 1994 · 77 · 84110.1016/0092-8674(94)90133-3 ↗
22. Mansour S. J. · Science · 1994 · 265 · 96610.1126/science.8052857 ↗
23. Wiesenauer C. A. · J. Am. Coll. Surg. · 2004 · 198 · 41010.1016/j.jamcollsurg.2003.10.004 ↗
24. Yip N. C. · Br. J. Cancer · 2011 · 104 · 156410.1038/bjc.2011.126 ↗
25. Dong Y. C. · Mol. Cell. Biochem. · 2012 · 370 · 8910.1007/s11010-012-1401-0 ↗
26. Ma L. Y. · Sci. Transl. Med. · 2014 · 6 · 252
27. Favata M. F. · J. Biol. Chem. · 1998 · 273 · 1862310.1074/jbc.273.29.18623 ↗
28. Ferrari M. · Trends Biotechnol. · 2010 · 28 · 18110.1016/j.tibtech.2009.12.007 ↗
29. Florence A. T. · J. Controlled Release · 2012 · 164 · 11510.1016/j.jconrel.2012.03.022 ↗
30. Chrastina A. · Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. · 2011 · 3 · 421
31. Cabral H. · Nat. Nanotechnol. · 2011 · 6 · 81510.1038/nnano.2011.166 ↗
32. Davis M. E. · Nat. Rev. Drug Discovery · 2008 · 7 · 77110.1038/nrd2614 ↗
33. Peer D. · Nat. Nanotechnol. · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
34. Heidel J. D. · Pharm. Res. · 2011 · 28 · 18710.1007/s11095-010-0178-7 ↗
35. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
36. Yuan Y. Y. · Adv. Mater. · 2012 · 24 · 547610.1002/adma.201202296 ↗
37. Yang X. Z. · Adv. Mater. · 2014 · 26 · 93110.1002/adma.201303360 ↗
38. Lai M. H. · ACS Appl. Mater. Interfaces · 2014 · 6 · 1082110.1021/am502822n ↗
39. Wang S. · ACS Appl. Mater. Interfaces · 2014 · 6 · 1070610.1021/am502579e ↗
40. Li K. · ACS Appl. Mater. Interfaces · 2014 · 6 · 1232810.1021/am502094a ↗
41. Ma Y. C. · ACS Appl. Mater. Interfaces · 2014 · 6 · 1617410.1021/am5042466 ↗
42. Cheng Y. · ACS Appl. Mater. Interfaces · 2012 · 4 · 532510.1021/am3012627 ↗
43. Quan L. · ACS Appl. Mater. Interfaces · 2014 · 6 · 1616610.1021/am5042115 ↗
44. Wang D. · Biomaterials · 2013 · 34 · 766210.1016/j.biomaterials.2013.06.042 ↗
45. Liu Y. · J. Controlled Release · 2008 · 129 · 1810.1016/j.jconrel.2008.03.022 ↗
46. Yang X. Z. · J. Controlled Release · 2011 · 156 · 20310.1016/j.jconrel.2011.07.035 ↗
47. Hu Y. · J. Immunol. Methods · 2009 · 347 · 7010.1016/j.jim.2009.06.008 ↗
48. Sun C. Y. · Adv. Healthcare Mater. · 2014 · 3 · 26110.1002/adhm.201300091 ↗
49. Sun T. M. · ACS Nano · 2011 · 5 · 148310.1021/nn103349h ↗
50. Liu Y. · J. Controlled Release · 2014 · 192 · 11410.1016/j.jconrel.2014.07.001 ↗
51. Merisko-Liversidge E. · Eur. J. Pharm. Sci. · 2003 · 18 · 11310.1016/S0928-0987(02)00251-8 ↗
52. Doi K. · Biol. Pharm. Bull. · 1994 · 17 · 141410.1248/bpb.17.1414 ↗
53. Merisko-Liversidge E. M. · Toxicol. Pathol. · 2008 · 36 · 4310.1177/0192623307310946 ↗
54. Larson T. A. · ACS Nano · 2012 · 6 · 918210.1021/nn3035155 ↗
55. Cao L. · BMC Gastroenterol. · 2011 · 11 · 7110.1186/1471-230X-11-71 ↗
56. Ernsting M. J. · J. Controlled Release · 2013 · 172 · 78210.1016/j.jconrel.2013.09.013 ↗